Skip to main content
Premium Trial:

Request an Annual Quote

Cornell President Jeffrey Lehman Slated to Discuss Post-Genomic Future in Inaugural Address; Mark Perry Appointed to Nuvelo Board; iBIO Names New Board Members; and Others

NEW YORK, Oct. 15 (GenomeWeb News) - Jeffrey Lehman was scheduled to be inaugurated as president of Cornell University at Weill Cornell Medical College in New York City today, and in his inaugural address planned to emphasize the critical importance of science and technology development in the "post-genomic era," the university said.

 

Lehman was also to address the need for efforts to "continue to transcend the boundaries of race and religion" amid scientific advances, according to a statement by the university.

 

Lehman is also participating in inauguration ceremonies at Cornell's main campus in Ithaca, NY, and at the Weill Cornell Medical College campus in Doha, Qatar. Lehman, a Cornell alumnus, was dean of the University of Michigan Law School for nine years before being named president of Cornell last December. For a webcast of today's event go to  http://inauguration.cornell.edu/nyc/index.cfm.


 

Mark Perry has been appointed to the board of directors of Nuvelo, the Sunnyvale, Calif., firm that resulted from the merger of Hyseq and Variagenics, the company said Oct. 14.

 

Perry, the executive vice president of operations at Gilead Sciences, replaces Jean-Francois Formela, a principal at Atlas Ventures, who resigned from the Nuvelo board on Oct. 13.

 

Perry has been at Gilead since 1994, and has served as vice president, general counsel and secretary, as well as CFO, before assuming his current duties in 2000. Prior to joining Gilead, Perry was a partner at the San Francisco office of the law firm Cooley Godward. He is also currently on the board of DNA Sciences and IntraBiotics Pharmaceuticals.


 

Norbert G. Riedel, Theron Odlaug, Dan Keeney, and Andy Hull have all been appointed to the board of directors of iBIO, the Illinois Biotechnology Industry Organization, iBIO said Oct. 14.

 

Riedel is chief scientific officer of cancer therapeutics firm Baxter International. Before joining Baxter in 1998, he served as head of biotechnology and core research at Hoechst Marion Roussel. He is also on the board of Genencor, Genome Therapeutics, and NanoMateria, and is on the board of directors of the Biotechnology Industry Organization, of which iBIO is the Illinois affiliate.

 

Odlaug is executive vice president of operations, administration, and strategic relations for Fujisawa Healthcare. He has been at Fujisawa's Deerfield, Ill., office since 1992. Prior to joining Fujisawa, Odlaug was vice president of quality for Miles (Bayer) in Elkhart, Indiana. He has also worked at Bayer's headquarters in  Leverkusen, Germany and at Baxter Healthcare.

 

Keeney is area vice president of state government affairs at GlaxoSmithKline, where he has worked since 1980.

 

Hull is director of business development at Takeda Pharmaceuticals North America, where he has worked since September 2002. Prior to joining Takeda, Hull worked in marketing and commercial development at Immunex for four years, and in marketing at Abbott Laboratories for 13 years.

 

These new iBIO directors will be introduced at the 4th annual iBIOMarketplace Conference, which is to be held November 12-13, 2003 at Navy Pier in Chicago.


 

Marvin Selter and Richard Wennenkamp have been appointed to the board of CytRx, a Los Angeles-based firm that focuses on RNAi-based therapeutics, the company said Oct. 10.

 

Selter and Wennenkamp replace Raymond Carnahan and Herbert McDade, who retired Oct. 10.

 

Selter is president of CMS, a management consulting firm, and serves on the boards of UCLA Medical Center, the San Fernando Economic Alliance, the Valley Economic Development Center and the California State University-Northridge Economic Development Center.

 

Wennenkamp is senior vice president of credit administration at Community Bank in Pasadena, Calif. Previously, he was managing director of credit product at Bank of America. He also was also executive director of the Ford Transition office, and was a staff assistant to the President of the United States.


 

Bruce Chabner, clinical director of the cancer center at Massachusetts General Hospital in Boston, has been appointed to the board of directors of Oncotech, a Tustin, Calif., molecular oncology lab services firm.  Chabner was formerly director of NCI's Division of Cancer Treatment for 13 years, during a 25-year tenure at the institute.

 

 

The Scan

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.

EHR Quality Improvement Study Detects Demographic-Related Deficiencies in Cancer Family History Data

In a retrospective analysis in JAMA Network Open, researchers find that sex, ethnicity, language, and other features coincide with the quality of cancer family history information in a patient's record.

Inflammatory Bowel Disease Linked to Gut Microbiome Community Structure Gradient in Meta-Analysis

Bringing together data from prior studies, researchers in Genome Biology track down microbial taxa and a population structure gradient with ties to ulcerative colitis or Crohn's disease.

Ancient Greek Army Ancestry Highlights Mercenary Role in Historical Migrations

By profiling genomic patterns in 5th century samples from in and around Himera, researchers saw diverse ancestry in Greek army representatives in the region, as they report in PNAS.